Opinion
Video
Author(s):
A panel medical oncologists provide an overview of circulating tumor DNA and its role in MRD (minimal residual disease) testing in the treatment of patients with colorectal cancer.
Exploring Unmet Needs to Optimize Neoadjuvant Therapy in Resectable CRC
Lenz Discusses the Prognostic and Predictive Value of HER2 Gene Expression in KRAS Wild-Type mCRC
Longest OS Reported From a Third-Line mCRC Randomized Trial Is Seen in ARC-9 Study
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
Murthy Highlights Second-Line Treatment Considerations in ER+/HER2– Metastatic Breast Cancer
OncLive’s June Roundup of Key FDA Approvals in Oncology
Dr Backhus on Surgical Eligibility in Borderline Resectable NSCLC
Dr Herbst on the Importance of Multidisciplinary Collaboration in NSCLC
Enhanced Clinical Education and Simplified Guidelines Needed to Address Germline Testing Gaps in Breast Cancer
Research Propels Additional Options into the Advanced HER2+ Breast Cancer Armamentarium